Detalles de la búsqueda
1.
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Lancet Oncol;
21(10): 1283-1295, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33002436
2.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Cancer;
125(22): 3974-3984, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31318460
3.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer;
19(1): 620, 2019 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31234810
4.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer;
19(1): 517, 2019 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31146717
5.
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
J Clin Oncol;
: JCO2301500, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537155
6.
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Clin Breast Cancer;
21(6): 539-551, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34154926
7.
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Cancer Chemother Pharmacol;
84(1): 175-185, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31102024
8.
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
J Clin Oncol;
35(2): 141-148, 2017 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28056202
9.
Caspases target only two architectural components within the core structure of the nuclear pore complex.
J Biol Chem;
281(2): 1296-304, 2006 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-16286466
Resultados
1 -
9
de 9
1
Próxima >
>>